The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*
Abstract
OBJECTIVE: To assess the effectiveness of moclobemide on smoking cessation and abstinence in heavy, dependent smokers. There is a strong association between smoking and depression, especially in dependent smokers. It was hypothesized that smoking is a self-medication to treat depression. Cigarette smoke has monoamine oxidase (MAO)-inhibitory properties, and smokers have lower MAO activity than non-smokers. METHODS: We used a randomized, double-blind, placebo-controlled parallel-group study. Placebo or moclobemide, 400 mg/day for 2 months and 200 mg/day during the third month, was given. Main outcome measures were self-reported and biochemically verified (plasma cotinine levels, < 20 ng/ml) abstinence rate. Secondary outcome measures were withdrawal symptoms, Montgomery-Asberg Depression Rating Scale, Hamilton anxiety rating scores, platelet MAO-B activity, and plasma dihydroxyphenylglycol as a measure of MAO-A activity. RESULTS: Eighty-eight smokers were randomized to receive moclobemide (n = 44) or placebo (n = 44). The continuous self-reported abstinence rate was higher with moclobemide than with placebo (intention-to-treat analysis until the end point, 6 months: p < 0.05; until the end of follow-up, 1 year: p = 0.09). The abstinence rate according to plasma cotinine levels showed a trend to effectiveness of moclobemide (end point: p = 0.13; follow-up: p = 0.12). Platelet MAO-B activity increased after smoking cessation but without a significant difference. Plasma dihydroxyphenylglycol levels did not change in the placebo group but decreased dose dependently in the moclobemide group. No difference occurred for withdrawal symptoms, Montgomery-Asberg Depression Rating Scale, and Hamilton anxiety scores. Cessation of moclobemide had no adverse effect. More subjects reported insomnia with moclobemide (n = 16) than with placebo (n = 3). CONCLUSION: In this preliminary study, the reversible, selective MAO inhibitor moclobemide facilitated smoking cessation in highly dependent smokers. Further studies with substantially more smokers are needed to evaluate the role of MAO inhibitors in smoking cessation and abstinence in smokers with high nicotine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
Smoking and Major Depression: A Causal Analysis
Kendler, K. S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130038007 · Cited by 792
Nicotine dependence, major depression, and anxiety in young adults
Breslau, N. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360033005 · Cited by 634
Nicotine Dependence and Major Depression: New Evidence From a Prospective Investigation
Breslau, N. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130033006 · Cited by 443
Predicting Smoking Cessation: Who Will Quit With and Without the Nicotine Patch
Kenford, S. L. (1994) · JAMA · doi:10.1001/jama.271.8.589 · Cited by 405
Clonidine, depression, and smoking cessation
Hughes, J. R. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03720190069036 · Cited by 95
Depression and the Dynamics of Smoking: A National Perspective
Anda, R. F. (1990) · JAMA · doi:10.1001/jama.1990.03450120053028 · Cited by 28
Heavy Smokers, Smoking Cessation, and Clonidine: Results of a Double-blind, Randomized Trial
Glassman, A. H. (1988) · JAMA · doi:10.1001/jama.1988.03720190031026
Cited by
The therapeutic potential of monoamine oxidase inhibitors
Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1883 · Cited by 1,363
Inhibition of monoamine oxidase B in the brains of smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A. P., et al. (1996) · Nature · doi:10.1038/379733a0 · Cited by 656
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Brain monoamine oxidase A inhibition in cigarette smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., Shea, C., Alexoff, D., MacGregor, R. R., Schlyer, D. J., Zezulkova, I., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14065 · Cited by 423
Smoking Cessation in Women: Special Considerations
Perkins, K. A. (2001) · CNS Drugs · doi:10.2165/00023210-200115050-00005 · Cited by 407
Metadata
- Authors
- Berlin, I., Saïd, S., Spreux-Varoquaux, O., Launay, J.-M., Olivares, R., Millet, V., Lecrubier, Y., & Puech, A. J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1995-10
- Volume
- 58
- Issue
- 4
- Pages
- 444-452
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1987776021
- Cited by
- 160
- References
- 9
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*. https://app.cochat.ai/papers/10.1016/0009-9236(95)90058-6
- The paper
- Berlin, I., Saïd, S., Spreux-Varoquaux, O., Launay, J.-M., Olivares, R., Millet, V., Lecrubier, Y., & Puech, A. J. (1995). A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/0009-9236(95)90058-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.